ClaroNav Kolahi Inc. Announces EU MDR Certification for Navient Surgical Navigation System

(BUSINESS WIRE)--ClaroNav Kolahi Inc. (CKI), a global developer and manufacturer of surgical navigation technologies, today announced that its Navient Surgical Navigation System has received certification under the European Union Medical Device Regulation, EU MDR.

The certification covers the Navient Image Guided Navigation System and its reusable surgical instruments, allowing CKI to continue offering Navient throughout the European Union under the EU MDR regulatory framework.

“EU MDR certification is an important milestone for CKI and demonstrates our continued commitment to meeting the highest standards for safety, quality, and regulatory compliance,” said Ahmad Kolahi, CEO of CKI.

Navient was previously certified under EU MDD and has received regulatory approvals including US FDA, Health Canada, China NMPA, and Japan PMDA. Today, Navient is installed in more than 70 countries, with an installed base of more than 250 systems worldwide.

For spine surgery, CKI has expanded the Navient platform with FluoroGuide 2D and its first in market CT/MRI to Fluoro Registration technology, integrating both preoperative CT and MRI with intraoperative 2D fluoroscopy for advanced 3D navigation.

“Access to advanced spine navigation remains limited worldwide, in part due to the high cost and complexity of intraoperative 3D imaging required by many navigation platforms,” said Ahmad Kolahi, CEO of CKI. “Navient’s CT/MRI to Fluoro Registration is designed to remove this barrier and make navigation more accessible and affordable. It enables hospitals and ambulatory surgery centers, ASCs, to use the conventional 2D C arm they already own while gaining access to advanced 3D navigation, reducing equipment cost and workflow complexity and, more importantly, helping reduce radiation exposure for both patients and operating room staff.”

About Navient

Navient is CKI’s surgical navigation platform for spine, cranial, ENT, and biopsy procedures. Designed around the principles: Intuitive. Precise. Portable., Navient combines advanced optical tracking, imaging integration, registration technologies, and AI assisted surgical planning in a compact and portable platform, making advanced navigation practical and accessible for a broader range of hospitals, ASCs, and outpatient surgical facilities.

About ClaroNav Kolahi Inc.(CKI)

CKI is a Toronto based medical technology company specializing in advanced surgical navigation systems. By combining intelligent, AI powered software with precision engineered hardware, CKI develops next generation solutions that empower surgeons with smarter tools and greater precision to enhance clinical confidence and improve patient outcomes.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20261007890668/en/

Permalink

https://www.aetoswire.com/en/news/54616649

Contacts

ClaroNav Kolahi Inc.

Website https://medical.claronav.com/

Email: info@claronav.com

LTM Expands Collaboration with Google Cloud to Help Accelerate Gemini Enterprise Adoption at Scale

 

MUMBAI, India - Wednesday, 07. October 2026

Collaboration brings together a dedicated Gemini Enterprise CoE and Customer Experience Center

 

(BUSINESS WIRE)--LTM, a Business Creativity partner to the world’s largest enterprises, today announced an expanded collaboration with Google Cloud to help accelerate adoption of Google Cloud’s Gemini Enterprise. The collaboration will help organizations build, deploy, and scale AI-powered solutions by combining Gemini Enterprise capabilities with LTM's deep industry expertise, engineering talent, and global delivery capabilities.

As part of this collaboration, LTM is making significant investments to strengthen its Gemini Enterprise capabilities through a dedicated Gemini Enterprise Center of Excellence (CoE), Specialized Talent and Delivery Capabilities and the development of Industry-Focused AI Solutions that will be showcased at the upcoming, state-of-the-art Gemini Enterprise Customer Experience Center. These efforts are designed to help organizations drive enterprise-wide AI adoption, operationalize intelligent workflows, and realize business value from AI at scale.

The collaboration focuses on three key pillars:

Gemini Enterprise Center of Excellence (CoE): Dedicated AI, cloud, and industry expertise to help enable enterprise-scale deployments of Gemini Enterprise.

Specialized Talent and Delivery: Forward Deployed Engineers, specialists in Google’s Gemini AI models, and advanced training & certification programs to help clients move high-value AI use cases from concept to production.

Industry-Focused AI Solutions and Gemini Enterprise Customer Experience Center: AI-powered solutions tailored to key industries, including BFSI, Manufacturing, Retail & CPG, Media & Entertainment, and Energy & Utilities, showcased at the upcoming Gemini Enterprise Customer Experience Center.

By combining LTM's domain expertise and transformation capabilities with Gemini Enterprise, LTM aims to help organizations move beyond isolated AI pilots. LTM’s collaboration with Google Cloud will help enable enterprises to build and orchestrate AI-powered workflows, deploy intelligent agents, and embed AI into business processes with the governance, security, and scale required for long-term business success.

"Enterprises are looking to move beyond AI experimentation and scale adoption with clear business outcomes. Through our expanded collaboration with Google Cloud around Gemini Enterprise, we are combining advanced AI capabilities, specialized talent, and industry expertise to help clients accelerate transformation and realize business value faster," said Krishnan Iyer, Chief Growth Officer, LTM.

To learn more about LTM’s collaboration with Google Cloud, click here.

About LTM

LTM — a Larsen & Toubro Group Company — is an AI-centric global technology services company and the Business Creativity partner to the world’s largest enterprises. We bring human insights and intelligent systems together to help clients create greater value at the intersection of technology and domain expertise. Our capabilities span integrated operations, transformation, and business AI — enabling new ways of working, new productivity paradigms, and new roads to value. Together with over 87,000 employees across 40 countries and our global network of partners, LTM owns outcomes for clients, helping them not just outperform the market, but Outcreate it. Read more at LTM.com.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20261007583213/en/

Permalink

https://www.aetoswire.com/en/news/54616938

Contacts

Media Contact: Gitanjali Sreepal |Global Media Relations | gitanjali.sreepal@ltm.com

Shah Rukh Khan and Rizwan Sajan Reunite For Shahrukhz Residences by Danube With Gauri Khan-Designed Penthouses

 Dubai, United Arab Emirates -

Following success of Shahrukhz by Danube, the commercial tower that sold out on launch day, Danube Properties announces next chapter of its iconic partnership with superstar Shah Rukh Khan with the launch of Shahrukhz Residences by Danube - a landmark fully furnished waterfront residential tower in Dubai Maritime City, with apartments starting at AED 1.65 million and a flexible payment plan of 30% during construction, and 70% upon handover.

Positioned as world’s first celebrity-named residential tower, Shahrukhz Residences by Danube sets a new benchmark for celebrity-inspired living, offering breathtaking views of the sea and the Dubai skyline.

Adding to its exclusivity, celebrated interior designer and SRK’s wife, Gauri Khan, has designed the penthouses, giving customers the opportunity to bring her distinctive design touch into their homes.

The tower will feature 40+ lifestyle amenities including a first-of-its-kind Longevity Lounge with cryotherapy, hyperbaric oxygen therapy, a red-light therapy bed and infrared sauna, alongside aqua-themed play areas, sports facilities, kids’ daycare, cycling and jogging tracks, and premium experiences inspired by “King style” living. The development will feature an exclusive King’s Club on the rooftop, while residents will also have access to a private yacht.  

Expressing his excitement, Shah Rukh Khan said: “I’m delighted to partner with Rizwan again for Shahrukhz Residences. The idea is to create a home that allows my fans to experience a similar lifestyle as mine. Having Gauri by my side in this project makes it even more special”

Rizwan Sajan, Founder and Chairman, Danube Group, said: “Shahrukhz Residences by Danube is a vision to create an address that people will aspire to own and remember for generations. After the phenomenal response to Shahrukhz by Danube, our customers asked us to bring this experience to residential living, and we listened. With Shahrukhz Residences, we are bringing together luxury, wellness, entertainment and premium design to create a truly iconic way of living — just like Shah Rukh’s and mine.”

About Danube Properties

Danube Properties, a subsidiary of Danube Group, founded in 1993 by Rizwan Sajan, is one of the UAE’s leading private real estate developers. Renowned for pioneering the 1% payment plan, the company develops fully furnished homes with 40+ lifestyle amenities and has built a strong reputation for quality construction and timely delivery.

Permalink

https://www.aetoswire.com/en/news/3102026577811

Contacts

Avinash Lohana

enquiry@danubeproperties.ae

+9718005757

ExaGrid Named Finalist for the MSP Channel Insights Awards 2026

 ExaGrid Nominated in 7 Categories for Industry Awards

(BUSINESS WIRE) -- ExaGrid, the world’s largest independent backup storage vendor providing Tiered Backup Storage for the fastest backups and restores, largest scale-out system with deduplication, and the most comprehensive security and AI-Powered Retention Time-Lock for Ransomware Recovery, today announced that it has been nominated in seven categories for the annual MSP Channel Insights Awards.

The MSP Channel Insights Awards celebrate innovation, expertise and success across the IT channel—recognizing the Managed Service Providers (MSPs), vendors, distributors, resellers and technology leaders driving customer outcomes and business growth.

Voting to determine the winner in each category is underway now and closes on October 30, 2026. Winners of the MSP Channel Insights Awards will be announced on November 26, 2026, at an awards ceremony in London.

The award categories that ExaGrid has been nominated for include:

Vendor of the Year

Vendor Channel Programme of the Year

Data Protection & Backup Vendor of the Year

Data Management & Analytics Innovation of the Year

Data Protection & Recovery Innovation of the Year

Technical Team of the Year

Company of the Year

ExaGrid continues to innovate its Tiered Backup Storage, and in the past year has added 4 SSD models to its product line in addition to its 8 HDD models, with the largest model scaling to an over 17PB full backup in a single scale-out system. ExaGrid also added support for Cohesity DataProtect to the list of 25+ industry-leading backup applications and utilities supported by the system, which include Veeam, Commvault, Rubrik, NetBackup, and many others. ExaGrid further deduplicates Cohesity deduplicated data for further storage and cost savings. In addition, ExaGrid has expanded on its already comprehensive security features by adding encryption over the wire to its NFS offering.

ExaGrid has also added more features for IT corporate data centers and MSPs in the past year, including the ability to set up, track, and report on backup data usage for specific shares per department or customer, as well as being able to set up a quote threshold to alert when the threshold is being exceeded, and allowing for ransomware recovery at the share level.

“We are honored that ExaGrid has become a finalist in seven award categories and look forward to seeing which vendors, service providers, and programs will be chosen by the voters,” said Bill Andrews, ExaGrid’s President and CEO. “ExaGrid remains committed to offering the best backup storage solution in the industry for MSPs and IT corporate data centers, with industry-leading technical support, the fastest backup and restore performance, and most security features in a backup storage system.”

About ExaGrid

ExaGrid provides Tiered Backup Storage with a unique disk-cache Landing Zone, long-term retention repository, scale-out architecture, and comprehensive security features, including AI-Powered Retention Time-Lock to recover from a ransomware attack. ExaGrid’s Landing Zone provides for the fastest backups, restores, and instant VM recoveries. The Repository Tier offers the lowest cost for long-term retention. ExaGrid’s scale-out architecture includes full appliances and ensures a fixed-length backup window as data grows, eliminating expensive forklift upgrades and forced product obsolescence. ExaGrid offers the only two-tiered backup storage approach with a non-network-facing tier (tiered air gap), delayed deletes, and immutable objects to recover from ransomware attacks.

ExaGrid has physical sales and pre-sales systems engineers in the following countries: Argentina, Australia, Benelux, Brazil, Canada, Chile, CIS, Colombia, Czech Republic, France, Germany, Hong Kong, India, Israel, Italy, Japan, Mexico, Nordics, Poland, Portugal, Qatar, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Turkey, United Arab Emirates, United Kingdom, United States, and other regions.

Visit us at exagrid.com or connect with us on LinkedIn. See what our customers have to say about their own ExaGrid experiences and learn why they now spend significantly less time on backup storage in our customer success stories. ExaGrid is proud of our +81 NPS score!

ExaGrid is a registered trademark of ExaGrid Systems, Inc. All other trademarks are the property of their respective holders.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20261006007082/en/

Permalink

https://aetoswire.com/en/news/0610202657852

Contacts

Media Contact:

Mary Domenichelli

ExaGrid

mdomenichelli@exagrid.com

 

Medisca and EUROAPI Form Strategic Partnership to Strengthen API Access for Pharmaceutical Compounding

 MONTREAL - Wednesday, 07. October 2026 AETOSWire  

This partnership brings together EUROAPI’s European pharmaceutical manufacturing capabilities and Medisca’s compounding expertise to expand access, strengthen its API portfolio and advance collaboration in peptides.

 

(BUSINESS WIRE)--Medisca and EUROAPI have formed a strategic partnership focused on expanding API access for pharmaceutical compounding, creating differentiated access in North America and establishing a broader framework for international growth and peptide collaboration.

For more than three decades, Medisca has built its business around the evolving needs of pharmaceutical compounders. That starts with the products it chooses to bring to market but extends much further to the manufacturers behind them, the documentation and technical information supporting them, and the quality systems that carry those products through to the customer.

The partnership with EUROAPI advances that approach. Under the new strategic partnership, Medisca becomes EUROAPI’s first strategic distribution partner focused on bringing its European-manufactured APIs to the North American compounding market. The collaboration includes exclusive supply arrangements for selected APIs and creates a framework to expand the offering over time, enter additional markets and advance new areas of pharmaceutical innovation.

For customers, the value goes beyond adding more APIs to a catalogue. The partnership creates a stronger connection between manufacturing expertise and the needs of the compounding market, supported by technical information, product documentation and Medisca’s direct customer insight. This allows Medisca to respond more closely to what compounders need today and continue adapting its offering as those needs change.

“This partnership marks an important milestone in the growth of Medisca,” said Peng Li, Chief Business Officer at Medisca. “EUROAPI brings deep manufacturing and technical expertise, with a strong focus on quality, green chemistry and sustainability. These strengths align with the evolving needs of the compounding market as personalized medicine continues to grow across telehealth, wellness and new areas of patient care. Together, we are expanding API access, building new opportunities across markets and advancing collaboration in peptides. We are proud to partner with EUROAPI and confident in the long-term potential of what we can build together.”

At the center of the partnership is a shared ambition to bring pharmaceutical manufacturing expertise, technical rigor and a strong quality foundation closer to the evolving needs of the compounding industry. Medisca’s approach begins at the source, with the manufacturer, the specifications and technical documentation behind an API and continues through the quality systems and controls that support it through to the customer. Through the partnership, EUROAPI will provide available technical and regulatory information relating to the APIs, strengthening the connection between manufacturing expertise and Medisca’s quality infrastructure. EUROAPI’s focus on green chemistry, and sustainability further supports Medisca’s commitment to responsible sourcing and broader social impact.

The relationship is also designed to grow. Medisca and EUROAPI intend to collaborate on customer initiatives, training and commercial activities, while adding new APIs over time and evaluating opportunities across additional markets.

Advancing collaboration in peptides

Peptides are an important area of strategic collaboration for Medisca and EUROAPI. As Medisca continues to expand its global peptide strategy for pharmaceutical compounding and personalized medicine, the companies intend to explore opportunities that combine Medisca’s market expertise with EUROAPI’s capabilities in complex API development and manufacturing. The collaboration creates a foundation to advance their work in peptides as the market continues to evolve.

“Medisca’s depth of expertise in pharmaceutical compounding and its close understanding of the market make it a strong strategic partner for EUROAPI,” said Frederic Robert, Chief Commercial Officer at EUROAPI. “This relationship creates new opportunities to broaden access to our APIs, expand our reach in the compounding market and develop our collaboration in areas such as peptides. We see significant potential to grow together over the long term.”

For Medisca, the partnership marks another step in its broader strategy to strengthen its API offering through direct relationships with pharmaceutical manufacturers, expand differentiated access for customers and build for the next generation of personalized medicine.

To explore EUROAPI-manufactured APIs available through Medisca, visit www.medisca.com

About Medisca

Founded in 1989, Medisca is a leader in personalized medicine and pharmaceutical supply chain solutions, with a vast portfolio of over 2,000 products complemented by a library of 10,000+ proprietary and customized medication formulas, expertise and services in pharmaceutical compounding, continuing healthcare education, and analytical testing. Providing finely-tuned solutions to diverse wellness sectors in numerous markets globally, Medisca is bridging the gaps in healthcare and empowering personalized wellness for all. For more information, visit www.medisca.com and follow us on LinkedIn, Facebook, and YouTube.

About EUROAPI

EUROAPI is focused on reinventing active pharmaceutical ingredients to sustainably meet customers’ and patients’ needs around the world. We are a leading player with approximately 200 products in our portfolio, offering a large span of technologies while also developing innovative molecules through our Contract Development and Manufacturing Organization (CDMO) activities.

With strong R&D capabilities and five manufacturing sites located in Europe, EUROAPI provides its clients with high-quality API solutions in more than 80 countries. Our 3000+ people are committed to building together the future of public health by advancing and securing access to essential active ingredients, at the core of the healthcare value chain. EUROAPI is listed on Euronext Paris: EAPI. Find out more at www.euroapi.com and follow us on LinkedIn.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20261002442058/en/

Permalink

https://www.aetoswire.com/en/news/54614246

Contacts

Medisca Communications

communications@medisca.com

1-800-665-6334

Corpay Cross-Border Extends Exclusive Partnership with WBSC

 Corpay will continue to provide the World Baseball Softball Confederation access to innovative global payments and comprehensive currency risk management solutions  

 

(BUSINESS WIRE)--Corpay, Inc.*, (NYSE: CPAY) a global leader in corporate payments, is pleased to announce that Corpay’s Cross-Border business has entered into a long-term agreement to extend their successful and exclusive collaboration as the Official Foreign Exchange (FX) Payments Provider of the World Baseball Softball Confederation (WBSC).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261006279113/en/

Since 2022, Corpay Cross-Border has delivered a range of corporate foreign exchange payment solutions to the WBSC, the international governing body for Baseball/Softball. With this multi-year extension, the WBSC and their members around the globe will continue to benefit from Corpay’s comprehensive currency risk management solutions and award-winning global payments platform.

“Over the past four years, we’ve had the privilege of serving as the Official FX Payments Provider for the WBSC,” said Brad Loder, Chief Marketing Officer, Corpay Cross-Border Solutions. “We take great pride in the trust the WBSC has placed in us, and we are thrilled to extend this partnership for multiple years. Our team looks forward to continuing to support the WBSC with its FX and cross-border payment needs as the organization continues to grow the sport of Baseball/Softball globally, including their participation as official medal disciplines at the Los Angeles 2028 Olympic Games.”

“We are delighted to extend our partnership with Corpay, whose expertise and reliability have provided tremendous value to the WBSC and our members around the world,” WBSC President Riccardo Fraccari said. “As an international sports federation operating across multiple continents and currencies, having a trusted partner that simplifies cross-border payments and helps manage foreign exchange risk is essential. This renewed agreement reflects the strength of our collaboration and our shared commitment to supporting the continued growth and global popularity of international Baseball/Softball.”

About Corpay

Corpay (NYSE: CPAY), the Corporate Payments and Expense Management Company, is an S&P 500 company with three primary B2B solution sets. Spend Management, provides corporate and virtual card programs and automates procure-to-pay. Cross-Border converts foreign currencies and establishes foreign bank accounts. Vehicle Solutions, controls fuel, tolls, parking and related vehicle spend. With Corpay, the more a business controls, the less it spends. To learn more, visit www.corpay.com.

About World Baseball Softball Confederation

Headquartered in Pully, Switzerland -- adjacent to Lausanne, the Olympic Capital -- the World Baseball Softball Confederation (WBSC) is the international governing body for the sport of Baseball/Softball including all the related disciplines. The WBSC has 207 National Federation and Associate Members in 142 countries and territories across Asia, Africa, Americas, Europe and Oceania, which represent a united Baseball/Softball sports movement that encompasses over 65 million athletes and attracts approximately 150 million fans to stadiums worldwide annually.

The WBSC governs all international competitions involving official National Teams including the WBSC Premier12 and Baseball World Cups (U-12, U-15, U-18, U-23 and Women's), Softball World Cups, (U-15 Women's, U-18 Women's, U-18 Men's, U-23 Men's, Women's and Men's), and official disciplines Baseball5 (Senior and Youth World Cups) and E-Sports as well as Baseball, Softball and Baseball5 events at the Olympic Games. The WBSC sanctions the World Baseball Classic.

*“Corpay” in this document primarily refers to the Cross-Border Division of Corpay, Inc. https://www.corpay.com/cross-border; a full listing of the companies that are part of Corpay Cross-Border is available here: https://www.corpay.com/compliance.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20261006279113/en/

Permalink

https://aetoswire.com/en/news/54613804

Contacts

Corpay Contact:

Brad Loder

Chief Marketing Officer

Corpay Cross-Border Solutions

+1 (647) 627-6635

brad.loder@corpay.com

World Baseball Softball Confederation Contact:

Richard Baker

Director of Media Department

+41 21 318 8240

richard.baker@wbsc.org

iQmetrix Launches Vendor Managed Inventory Integration with Valor Communication

 

VANCOUVER, British Columbia - 

The addition of Valor Communication marks another step in the rapid expansion of the iQmetrix Partner Ecosystem, bringing clients a growing network of integrated partners that work natively inside the platform they already run their business on.

 

(BUSINESS WIRE)--iQmetrix, the global provider of Intelligent Commerce Operating Systems for telecom, is launching a Vendor Managed Inventory integration with Valor Communication, a factory-direct wireless accessory manufacturer and distributor serving carriers, retailers, and dealers since 1997. Built into the iQmetrix Intelligent Commerce Operating System, the integration connects Valor's assortment directly to the platform telecom retailers already run their business on – so replenishment runs on real sell-through data instead of guesswork, and approved accessories move from Valor's floor to the peg without manual reordering. The integration will be available to retailers across the iQmetrix client base. The addition of Valor Communication marks another step in the rapid expansion of the iQmetrix Partner Ecosystem, bringing clients a growing network of integrated partners that work natively inside the platform they already run their business on.

The initial rollout features a curated assortment of the newest MyBat Pro products in updated branding and packaging, led by protection for the latest iPhone generation and a new power lineup. Behind that assortment, Valor owns its manufacturing. Product development and tooling run through Valor's own Shenzhen factory, with packaging, distribution, and fulfillment handled in-house from California and Texas – which means shorter lead times on device launches, tighter cost control, and one accountable partner instead of a chain of handoffs.

“Accessory inventory is where a lot of retailers quietly lose margin – overstocked on last year's model, out of stock on this year's. Our VMI integration with iQmetrix fixes that inside the system retailers already use: real sell-through data driving real replenishment decisions, managed by us. What makes it work is that we own the line end to end – we design it, we build it, we ship it – so when a retailer needs product moved, there's no third party in the middle. For iQmetrix clients, that means a 16,000-SKU catalog, six in-house brands covering every price point, and one partner accountable from concept to peg.”

Tom Redington

VP of Sales, Valor Communication

“The best partnerships are the ones that solve a problem our clients deal with every day,” said Channing Kochylema, Director, Partner Ecosystem at iQmetrix. “Accessory inventory has always been a manual, disconnected process for wireless retailers – this VIS integration fixes that. Valor's catalog now flows directly into RQ, with replenishment driven by real sell-through data instead of guesswork. We're excited to help our clients turn accessory attach into the high-margin opportunity it should be.”

Channing Kochylema

Director, Partner Ecosystem 

About Valor Communication

Valor Communication has spent nearly three decades doing something most accessory suppliers don’t: owning the whole line. Founded in 1997, Valor develops, manufactures, packages, distributes, and fulfills its own products rather than brokering someone else’s. That vertical control is what lets Valor move fast on new device launches, hold pricing through volatile cost cycles, and build programs other suppliers have to outsource.

The result is a portfolio of 16,000+ active SKUs across protection, power, audio, attachables, and wearables, anchored by six in-house brands – MyBat Pro, MyBat, AmpNergy, echelon, baseline, and EcoBlvd – spanning premium to value so a retailer can fill an entire peg wall from a single partner. Alongside those brands, Valor curates a selection of third-party brands, giving retailers one purchase order instead of a dozen vendor relationships.

Valor pairs that catalog with the operational and marketing infrastructure retailers need to actually sell it: 250,000+ square feet of fulfillment across California and Texas, vendor managed inventory, merchandising and display support, sales enablement materials, and dealer incentive programs. Commercially, Valor is built for how wireless retail actually buys – no minimum order quantities, flexible payment terms, and free ground shipping on orders of $100 or more. Products already reach 21,000+ retail locations today.

About iQmetrix

iQmetrix is the global provider of Intelligent Commerce Operating Systems for telecom. It replaces fragmented legacy stacks with a modern, modular operating layer that orchestrates telcos, retailers, vendors, and OEMs into one intelligent flow across channels and markets. The result is less complexity, lower cost, and the speed to move ahead. 

For more than 27 years, iQmetrix has  been helping the leading brands in telecom grow by providing best-in-class software, services, and expertise. Its solutions power $17BN in sales annually, handling nearly 53 million invoices and more than 28 million activations, and are used by more than 370,000 telecom professionals across more than 10,000 locations. iQmetrix is a privately held software-as-a-service (SaaS) company with employees in Canada, the U.S., India, and Europe. For more information, please visit www.iQmetrix.com.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20261007303672/en/

Permalink

https://aetoswire.com/en/news/54617256

Contacts

Media Contact

media@iqmetrix.com

 

Rivercell Launches With $25 Million to Build Data Platforms and AI Models That Predict How Human Cells Respond to Treatment

PARIS - Wednesday, 07. October 2026

Founded by serial entrepreneur and CEO, Yann Fleureau, and former AI research leader at Novartis and Owkin Eric Durand, Rivercell aims to generate high-resolution data on how human cells respond to treatments at scale and train AI models to predict their effects, ultimately accelerating the discovery and development of cures.

Seed round led by HV, with participation from HCVC, Alven, and Bpifrance Digital Venture, to scale Rivercell's proprietary data engine and automated wet lab, and ship the first AI world model of the cell trained on a new data substrate.

Eric Durand joins as co-founder and Chief Science Officer (CSO). At Novartis, he successfully supported around 300 drug programs before building Owkin’s data science team as Chief Data Science Officer, giving him first-hand insight into the data that today's bio world models are missing.

Leading researchers in AI for biomedicine, Dr. Charlotte Bunne (EPFL) and Prof. Fabian Theis (Helmholtz Munich), join the Scientific Advisory Board.

The platform is designed to be a horizontal, indication-agnostic discovery engine, applicable across indications like oncology, immunology, rare diseases, and cardiometabolic disease.

 

(BUSINESS WIRE) -- Rivercell, a Paris-based biotechnology and AI company building its own data infrastructure on how human cells respond to any treatment and training a world model of the cell that can predict those responses, today announced a $25 million seed round led by HV. HCVC, Alven and Bpifrance Digital Venture also participated in the round, which will fund the scale-up of Rivercell’s proprietary data generation platform, the expansion of its wet lab in Paris (a lab working with chemicals and biological samples), and the launch of its AI Virtual Cell program. Being indication-agnostic, Rivercell's world model can drive groundbreaking discovery across any cell behavior that leads to disease because it learns the underlying rules of how human cells respond to drugs and genetic changes, not the features of a single disease.

Rivercell was started in summer 2025 by CEO Yann Fleureau, the engineer-turned-entrepreneur behind AI company Cardiologs, joined in 2026 by CSO Eric Durand, an AI scientist and former C-Level executive at AI drug discovery unicorn Owkin. Rivercell builds a proprietary platform that generates massive, high-quality pre-training datasets to train its “AI virtual cell” (AIVC) model. AIVC is a world model designed to predict how human cells respond to a drug or genetic change in silico, reducing the overall need for physical wet-lab experiments significantly. Rivercell’s long-term goal is to fundamentally change drug discovery by accelerating and redesigning it. Developing a single drug can take years and be costly, with the industry investing nearly $300 billion in R&D each year.

Realizing this potential depends on data. AlphaFold revolutionized protein structure prediction because it could draw on decades of publicly available protein structure data. Building a comparable model of the cell is a far greater challenge: it requires diverse, multimodal, time-resolved data on how cells respond to perturbations. No such dataset exists at the scale needed today, so Rivercell is creating that foundation. The company generates a large-scale biological dataset and uses it to train its AI virtual cell. Because today's laboratory instruments were not designed for this application, Rivercell is developing an innovative, purpose-built platform capable of capturing the data at the scale required to pre-train its world model. The company describes this platform as the "GPU for the bio data center" of the future.

“A world model of the cell is the opportunity of the century in medicine. The missing piece is data: how cells change over time and under treatment, seen through multiple lenses and at multiple layers, captured at scale. Building that data engine in Europe is strategic, not only for Rivercell but for the continent's place in AI and biology," said Yann Fleureau, co-founder and CEO of Rivercell.

Engineer and serial entrepreneur Yann Fleureau previously co-founded and led AI diagnostics company Cardiologs, raising several funding rounds before its nine-figure acquisition by Philips in 2021. Data scientist Eric Durand was director of oncology data science at Novartis and served as Chief Data Science Officer at Owkin before co-founding bio foundation model company Bioptimus, which raised $76 million.

“AI is already rewriting how we understand the chemistry of life, from protein structure to molecular design. The next frontier is predicting how cells behave, and that requires a full-stack approach that combines a novel platform, automated wet labs, and world models. Yann and Eric bring exactly this combination of expertise, and with its footing in both Paris's AI ecosystem and Basel's pharma cluster, Rivercell is uniquely positioned to lead it,” said Maxi Pethö-Schramm, Principal at HV.

Rivercell is also backed by scientific advisors including Dr. Charlotte Bunne and Prof. Dr. Dr. Fabian Theis and angel investors including founders and executives from Twist Bioscience, DNA Script, Agilent and Abivax/Ipsen.

“AI virtual cells will transform how we understand and engineer biology. Rivercell’s ambition to unite large-scale perturbation experiments with AI simulation is why I’m excited to join its Scientific Advisory Board,” said Dr. Charlotte Bunne, Assistant Professor, Artificial Intelligence in Molecular Medicine at EPFL.

"Understanding how cells respond to perturbations, over time rather than in snapshots, is one of the big open problems in biology. Rivercell is tackling it at scale, with both the data and the AI models to match. I'm thrilled to join its Scientific Advisory Board," closed Prof. Fabian Theis, Director of the Computational Health Center at Helmholtz Munich, Scientific Director of Helmholtz AI and Professor of Mathematical Modeling of Biological Systems at the Technical University of Munich.

About Rivercell

Rivercell is building the data engine and the AI model that predict how living cells respond to drugs and genetic changes. Its proprietary in-house platform produces interventional, time-resolved, multimodal single-cell data at scale, which trains Rivercell's own AI world model of the cell. Rivercell is based in Paris, France. Learn more at rivercell.ai.

About its founders:

Yann Fleureau, a graduate of École Polytechnique and UC Berkeley, co-founded and led Cardiologs, the market leader in AI-based cardiac diagnostics, raising successive venture rounds before Philips acquired the company in 2021 in a nine-figure exit. Its technology now supports the diagnosis of more than two million patients a year. He also co-founded Numina, a non-profit developing AI for frontier reasoning in mathematics and physics.

Eric Durand, Rivercell’s co-founder and Chief Scientific Officer, spent seven years as Director of Data Science in oncology at Novartis, supporting hundreds of drug programs. He went on to serve as Chief Data Science Officer at Owkin, where he grew the AI team from 20 to more than 100 engineers, and co-founded the biology foundation-model company Bioptimus, which raised $76 million. Earlier in his career, he built one of the first consumer ancestry algorithms at 23andMe. He holds a PhD in statistics and population genetics and conducted postdoctoral studies at UC Berkeley.

About HV

HV is one of the leading early-stage and growth investors in Europe. With nine fund generations in 26 years and €2.8 bn in managed assets, HV is one of the continent's most active investors. The investment team has many years of experience in identifying European startups with great potential for success. In addition to international success stories like Flix, Zalando, Delivery Hero, Sumup, and Depop, innovation leaders such as Quantum Systems, Marvel Fusion, AMI Labs, Neura Robotics, Enpal, and Isar Aerospace, are also part of the portfolio. HV has invested in more than 290 internet and technology companies, supporting startups with ticket sizes ranging from €0.5m to €60m. It is one of Europe's few venture capital firms that can finance startups through all growth phases. HV has a team of more than 60+ investment and operations professionals who provide a variety of perspectives and expertise across the venture capital landscape.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20261007283522/en/

Permalink

https://www.aetoswire.com/en/news/0710202657889

Contacts

Rivercell Media contact:

press@rivercell.ai

HV Media contact:

Kekst CNC

hvcapital@kekstcnc.com

OPEX® Corporation Offers a Simplified, One-Touch Document Scanning Solution with the Introduction of Axis™

 (BUSINESS WIRE)--OPEX® Corporation, a global leader in Next Generation Automation providing innovative solutions for warehouse, document and mail automation, has announced the launch of Axis™, a new document scanner that brings the benefits of one-touch scanning to a simplified, single-bin configuration. Designed for document capture workflows where minimal document preparation, mixed media handling or operational simplicity are priorities, Axis bridges the gap between OPEX’s desktop scanner series and its multi-bin production scanner portfolio.

“We developed Axis in direct response to market demands,” said Dann Worrell, President, Document and Mail Automation, OPEX. “Our customers want to simplify their scanning processes, reduce operating costs, and improve quality. Axis delivers on these priorities by combining our minimal-prep, One-Touch scanning technology with a single-bin design. With a lower market accessible entry point, Axis helps customers process documents more efficiently while achieving more consistent results.”

OPEX’s newest solution is built on a production-class transport architecture, supporting both continuous batch scanning and scan-from-folder workflows on a single platform. It manages auto feed and drop feed, and handles mixed sizes, weights and conditions. Capable of scanning up to 120 ppm, Axis is designed for any scanning operation that handles mixed document types and spends more significant hours prepping documents before scanning. It is ideal for businesses looking for simplified deployment, flexible workstation options, and a focused, purpose-built alternative to multi-bin production systems.

Axis is available in two models to support varying deployment requirements. The Axis includes an integrated workstation with system component mounts, while the AXIS-M (mobile) offers a foldable support structure designed for relocation between work areas or sites.

“Our team is always focused on building new solutions that enable all types of businesses to improve workflow, drive efficiencies, and solve challenges,” said Scott Maurer, President, International Division, OPEX. “Axis represents the midpoint in our document scanning portfolio, providing a cost-effective approach for advanced document capture applications when physical sorting and dedicated, MICR-based payment processing aren’t required.”

The Axis document scanner enables operators to capture documents with a streamlined, one-touch process, reducing manual handling and improving productivity. Axis supports scan-on-demand, overflow, and distributed capture operations, without requiring workflow-specific scanner configurations. With its single output design, Axis is well suited for archive, backfile conversion, and folder-based scanning applications, where documents are captured and returned in their original order. Additional features include an integrated 22” touchscreen display, a rescan feeder, a document conditioning roller, ultrasonic sensors to detect multi-feed conditions, and more.

Axis joins the existing portfolio of advanced document scanning solutions at OPEX, which includes Falcon®+, Falcon®+ RED™, Gemini®, and Velo™ Powered by Inotec®. It is the first OPEX-designed hardware platform to support a customer-supplied PC Controller and planned TWAIN connectivity, expanding deployment flexibility and integration options while maintaining compatibility with OPEX workflows.

OPEX will debut Axis at ARMA InfoCon 2026, scheduled from October 25 through 28, at the Savannah Convention Center in Georgia, with live demonstrations in Booth #803. Axis will also be available for demonstration at our world headquarters in Moorestown, NJ, and EMEA headquarters in Duisburg, Germany.

About OPEX

OPEX® Corporation is a global leader in Next Generation Automation, providing innovative, unique solutions for warehouse, document and mail automation. With headquarters in Moorestown, NJ—and facilities in Pennsauken, NJ; Plano, TX; France; Germany; Switzerland; the United Kingdom; and Australia—OPEX has over 1,600 employees who are continuously reimagining and delivering customized, scalable technology solutions that solve the business challenges of today and in the future. For more information, visit opex.com.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20261006807452/en/

Permalink

https://www.aetoswire.com/en/news/54616480

Contacts

For Additional Information

Laura Evans

levans@opex.com

+1.856.727.1100 x 5012

 

illumynt Launches Talorem®, Bringing Engineering Rigor to Smarter Technology Reuse

 COLUMBUS, Ohio -

Proprietary technology platform delivers faster receiving, better asset intelligence, more accurate grading and higher recovery value.

(BUSINESS WIRE) -- illumynt, a technology-driven lifecycle management company serving AI infrastructure, hyperscale, OEM and enterprise environments, today announced the launch of Talorem®, its proprietary technology platform designed to bring greater precision, intelligence and recovery value to the management of advanced computing assets.

Talorem is illumynt’s proprietary technology platform for engineering-grade testing, refurbishment, recovery, grading and asset intelligence at scale. As the technology foundation behind illumynt’s advanced computing lifecycle operations, Talorem brings together OEM-grade testing and qualification, clean room component recovery, centralized grading infrastructure and analytics to create greater intelligence at every stage of the asset lifecycle-enabling faster processing, more accurate grading and higher recovery value.

“Talorem represents how we believe technology lifecycle management needs to evolve,” said Jörg Herbarth, CEO of illumynt. “The more precisely we can identify, test and understand an asset, the better decisions we can make about its next use—and the more value we can recover for our customers.”

The Engineering Rigor Behind Smart Reuse

As infrastructure becomes more complex and refresh cycles accelerate, traditional approaches to IT asset disposition can be limited by manual processes, generalized testing and incomplete asset data. Talorem applies engineering-grade methodology and standardized processes to determine whether technology should be redeployed, repaired, remarketed, harvested for high-value components or responsibly recycled.

Just as importantly, Talorem creates structured asset data throughout the process. As more equipment is processed, that intelligence builds over time, creating more accurate benchmarks, supporting more defensible recovery pricing and enabling lifecycle decisions grounded in observed asset performance rather than assumptions.

Built for the Economics of Advanced Computing

For hyperscalers, OEMs and enterprises, the economics of technology disposition are changing. Hardware is becoming more specialized, individual components can retain significant value even when a larger system reaches end of life, and accurate testing and grading can materially affect decisions around reuse, resale and recovery.

Talorem is built around that reality, combining engineering discipline with asset intelligence to help organizations understand not simply what an asset is, but what it can still do and what it is still worth.

“Circularity is increasingly an engineering and data challenge, not simply a logistics challenge,” Herbarth added. “Talorem gives us the ability to make smarter reuse and recovery decisions at scale while giving our customers greater visibility into the condition and value of their technology.”

About illumynt

illumynt is a technology-driven lifecycle management company helping organizations maximize the value of complex IT and advanced computing infrastructure. Through engineering-grade diagnostics, repair, component recovery, secure processing and asset intelligence, illumynt helps hyperscalers, OEMs and enterprises extend technology lifecycles, recover greater value and make more informed infrastructure decisions.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20261006382527/en/

Permalink

https://www.aetoswire.com/en/news/0610202657856

Contacts

Alyson Kaye

Alyson.kaye@illumynt.com

617.407.6381

 

30 Years of Restylane®: Reshaping the Aesthetics Field Through Science-Led, Patient-Centric Innovation

 ZUG, Switzerland - Tuesday, 06. October 2026 AETOSWire  

Galderma celebrates the 30th anniversary of Restylane, its pioneering range of hyaluronic acid (HA) injectables that established the category as the first to market1

With three decades of innovation across technology, packaging, and treatment areas, Restylane continues to meet growing aesthetic needs, including emerging areas such as medication-driven weight loss, skin quality and menopause1-11

This year’s milestones include the approvals of Restylane Shaype™ in the European Union (EU) for enhancement of the chin region, the new state-of-the-art Restylane syringe in the EU, United States (U.S.), and Canada, and Restylane Volyme™* in the U.S. for temple hollowing, with a dual-layer patent-pending technique leveraging both needle and cannula12-18

With more than 80 clinical trials, 180 publications, around 407,000 patients evaluated for safety, and 77 million treatments administered worldwide, Restylane remains a pioneer in science-backed aesthetic innovation and continues to shape the future of HA injectables1-3,19,20

 

(BUSINESS WIRE) -- Galderma (SIX: GALD), the pure-play dermatology category leader, celebrates 30 years since Restylane was launched in Europe as the first hyaluronic acid (HA) injectable.1 With HA closest to the skin’s own, Restylane is designed to deliver personalized, natural-looking outcomes that meet diverse patient needs across key areas of the face, décolletage, and hands.8,10,12,21-31 With three decades of innovation across technology, packaging, and treatment areas, Restylane remains at the forefront of innovation, evolving from its original NASHA®, technology into a comprehensive portfolio spanning three distinct technologies: NASHA HD™, NASHA®, and OBT™.1,8,21,22 Together, these technologies offer solutions ranging from firmer gels that provide contouring and structural support, to soft, flexible formulations that smooth facial lines and wrinkles for a more youthful look.8,12,21-31

The Restylane portfolio has most recently achieved EU Medical Device Regulation certification for the products created with NASHA HD™, NASHA®, and OBT™ technologies.12,23-29 As one of the world's most rigorous medical device regulatory frameworks, the certification reinforces confidence in the strong safety profile, quality standards and scientific foundation behind the portfolio.32

   

 “Restylane's 30-year journey is a testament to Galderma's enduring commitment to science-led innovation in aesthetics. Supported by extensive clinical experience – including more than 400,000 patients evaluated for safety – and robust real-world data, Restylane has helped define aesthetics, setting a high standard for safety, efficacy and natural-looking results since it launched as the first HA injectable three decades ago. With market penetration still relatively low, significant opportunities remain to expand adoption, and as we look to the future, we will continue to build on this foundation through innovation that reinforces the essential role of HA injectables in the future of aesthetics.”

BALDO SCASSELLATI SFORZOLINI, M.D., Ph.D.

GLOBAL HEAD OF R&D

GALDERMA

 

   

Expanding Restylane’s versatility to support tailored aesthetic outcomes

Restylane continues to expand treatment possibilities through new technologies, indications, and devices.

Restylane Shaype was recently approved in the EU for correction and enhancement of the chin region.12 Powered by Galderma’s new NASHA HD™ technology, it is the firmest HA injectable gel available among facial filler market leaders, delivering a unique bone-mimicking effect that enables immediate, natural-looking structural enhancement in the lower face.12,21,33 Restylane Shaype is the first minimally invasive injectable aesthetic option to provide structure in this increasingly important treatment area, which has previously largely relied on surgical implants.21

A new state-of-the-art Restylane syringe was also approved in the EU, U.S. and Canada earlier this year, for use with the NASHA® lidocaine Restylane products in multiple facial indications.13-15 It was designed in collaboration with over 70 aesthetics practitioners to be optimized for ergonomic functionality, ease of aspiration, and ease of operation.34-37 It has compact blister-free packaging that is 100% recyclable and reduces in-clinic waste by up to 30% based on volume reduction.38,39 A survey of over 300 healthcare professionals in Brazil who had personal experience using the Restylane syringes found that 89% preferred the next-generation syringe over the standard syringe.40 The next-generation syringe complements Galderma’s patented SmartClick™ syringe for Restylane Skinboosters™, which monitors each micro-dose, allowing injectors to focus on technique ​and placement for enhanced patient safety, precision and control.31,41

As global demand grows for treatments that address the evolving effects on the skin of aging, menopause, and weight loss, Restylane Volyme received U.S. approval in March for the correction of temple hollowing with a dual-layer patent-pending technique leveraging both needle and cannula.16-18 Temple volume loss can disrupt facial balance and harmony, and contribute to a tired, sunken, and aged appearance, a challenge increasingly seen in people undergoing medication-driven weight loss and experiencing age- and hormone-related changes, including menopause.6,18,42

   

 “Restylane has been a trusted part of my practice for many years, thanks to the constant innovations brought to the portfolio in terms of product, indications and even packaging. Today, I treat an increasingly diverse range of individuals seeking personalized, natural-looking results, so having a versatile portfolio that goes beyond volumizing and can provide lift, contour, definition and skin quality improvements across multiple areas of the face and body is invaluable. Supported by decades of science, Restylane gives me the confidence to tailor treatments to each patient’s unique anatomy, goals and stage of life.”

DR. LUDDI LUIZ OLIVEIRA

PLASTIC SURGEON

BRAZIL 

 

   

Restylane expands access to injectable aesthetics for new patient segments

Restylane remains highly relevant in addressing some of today’s most significant aesthetic trends and needs including medication-driven weight loss, menopause and skin quality.

Interim results from an investigator-initiated trial showed that combining Restylane Skinboosters with Sculptra® – the first proven regenerative biostimulator – drove progressive improvements in hydration, skin barrier function, and overall skin quality in menopausal women.4,43-46 These results are reinforced by consensus guidelines concluding that Restylane Skinboosters can complement Sculptra in the décolletage for comprehensive body rejuvenation.47

Additionally, Restylane also has an important role in addressing the aesthetic concerns of patients experiencing facial volume loss associated with medication-driven weight loss.11 The combination of Restylane Lyft™ or Volyme with Sculptra has been shown to deliver visible improvements in skin quality and significantly enhance patient satisfaction and emotional wellbeing.11

Supported by 30 years of innovation and more than 77 million treatments administered worldwide, Restylane has helped define the HA injectable category and continues to shape the future of aesthetic medicine.1-3 With more than 80 clinical trials, 180 publications and around 407,000 patients evaluated for safety, its legacy is built on extensive scientific evidence and clinical experience.3,19 These milestones demonstrate Galderma’s ongoing commitment to using its unique dermatology expertise and strong portfolio to meet the needs of patients and healthcare professionals today and tomorrow.

*Restylane Volyme is known as Restylane Contour™ in the U.S.

About the Restylane portfolio

Restylane HA treatments are designed differently to go beyond volumizing for natural-looking results.2,24,48 Our HA is minimally modified and our innovative manufacturing process preserves its biocompatibility while creating individual products designed for a specific purpose.7,10,49 Powered by NASHA HD™, NASHA®, and OBT™ technologies, Restylane offers gels with the highest firmness to the highest flexibility, enabling personalized treatments that deliver structural support, natural-looking results, and a healthy glow.8,21,22,33 Trusted for almost three decades, our HA gels work in sync with your skin for 100% natural-looking results.2,50,51 Approved indications vary by market.

About Galderma

Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.

References

Galderma. Data on file. MA-57232 [Updated]. 77 Million treated.

Di Gregorio C, et al. 25+ years of experience with the Restylane portfolio of injectable HA fillers for facial aesthetic treatment. E-poster presented at AMWC; March 27-29, 2024; Monaco.

Galderma. Data on file. MA-55607. Restylane® 27 years data publications analysis.

Nikolis A, et al. A comprehensive interim analysis of skin hydration, barrier function (TEWL), elasticity, and patient satisfaction across two treatment arms. Interim Data on File. April 2026.

Nikolis A, et al. Evaluating the role of small particle hyaluronic acid fillers using micro-droplet technique in the face, neck and hands: a retrospective chart review. Clin Cosmet Investig Dermatol. 2018;11:467–475. doi: 10.2147/CCID.S175408.

Humphrey CD & Lawrence AC. Implications of Ozempic and other GLP-1 receptor agonists for facial plastic surgeons. Facial Plast Surg. 2023;39:719-72.

Edsman K, et al. Gel properties of hyaluronic acid dermal fillers. Dermatol Surg. 2012;38:1170–1179. doi: 10.1111/j.1524-4725.2012.02472.x.

Belmontesi M, et al. Injectable non-animal stabilized hyaluronic acid as a skin quality booster: An expert panel consensus. J Drugs Dermatol. 2018;17(1):83– 88.

Kim J. Effects of injection depth and volume of stabilized hyaluronic acid in human dermis on skin texture, hydration, and thickness. Arch Aesthet Plast Surg. 2014;20:97-103. doi:10.14730/aaps.2014.20.2.97.

Galderma. Data on file. MA-58650. Degree of modification of HA fillers.

Galderma. Data on file. Somenek M and Lorenc P. A multi-center, open-label study to evaluate the synergistic effects of biostimulator and dermal fillers for cheek augmentation and correction of contour deficiencies: Nine-month topline results.

Restylane® Shaype EU IFU.

Galderma. Data on file. U.S. FDA Restylane syringe PMA supplement approval letter.

Galderma. Data on file. Health Canada Restylane Medical Device License.

Galderma. Data on file. Dekra Restylane next generation syringe report.

Restylane® Contour™. US IFU.

Galderma. Data on file. MA-63365 Study Report. 2025.

Galderma. Data on file. Restylane Contour temple investigator closeout meeting executive summary. 2025.

Park KE, et al. Response of 21 hyaluronic acid fillers to recombinant human hyaluronidase. Plast Reconstr Surg Glob Open. 2023;11:e5457. doi:10.1097/GOX.0000000000005457.

Verpaele A, Strand A. Restylane SubQ, a non-animal stabilized hyaluronic acid gel for soft tissue augmentation of the mid-and lower face. Aesthetic Surg J. 2006;26(Suppl.):S10–17. doi: 10.1016/j.asj.2005.09.009.

Nikolis A, et al. Effectiveness and safety of a new hyaluronic acid injectable for augmentation and correction of chin retrusion. J Drugs Dermatol. 2024;23(4):255–61. doi: 10.36849/JDD.8145.

Öhrlund Å, et al. Differentiation of NASHA and OBT hyaluronic acid gels according to strength, flexibility, and associated clinical significance. J Drugs Dermatol. 2024;23(1):1332–6. doi: 10.36849/JDD.7648.

Restylane® Lyft™. EU IFU.

Restylane® Classic. EU IFU.

Restylane® Eyelight™. EU IFU.

Restylane® Defyne™. EU IFU.

Restylane® Volyme™. EU IFU.

Restylane® Kysse™. EU IFU.

Restylane® Refyne™. EU IFU.

Restylane® Skinboosters Vital Lidocane™. EU IFU.

Restylane® Skinboosters Vital Light Lidocane™. EU IFU.

European Medicines Agency. Available online. Accessed October 2026.

Galderma. Data on file. MA-56724. 2023. Global rheology data (xStrain and G´ including Restylane SHAYPE).

Galderma. Data on file. MA-64737.

Galderma. Data on file. MA-56005.

Galderma. Data on file. Design and development of the next generation syringe.

Galderma. Data on file. MA-59168.

Galderma. Data on file. Vimer S.r.l. Declaration of recycling compliance. 2025.

Galderma. Data on file. MA-63907.

Galderma. Data on file. Restylane next generation syringe HCP survey.

Landau M, Fagien S. Science of Hyaluronic Acid Beyond Filling: Fibroblasts and Their Response to the Extracellular Matrix. Plast Reconstr Surg. 2015;136(5S):188S–195S. doi: 10.1097/PRS.0000000000001823.

Qin J. Ozempic face: A new challenge for facial plastic surgeons. JPRAS. 2023;81:97-98. doi: 10.1016/j.bjps.2023.04.057.

Galderma. Data on File. MA-60875. A Single Center, Double-Blinded, Split-Body, Randomized Clinical Trial of Injectable Poly-L-Lactic Acid for Volumization and Adipogenesis of the Hip Dell.

Huth S, et al. Molecular Insights into the effects of PLLA-SCA on Gene Expression. J Drugs Dermatol. 2024;23(4):285-288. doi: 10.36849/JDD.7791.

Waibel J, et al. A randomized, comparative study describing the gene signatures of poly-l-lactic acid (PLLA-SCA) and calcium hydroxylapaptite (CaHA) in the treatment of nasolabial folds. Poster presented at IMCAS 2024, February 1-3, 2024, Paris, France.

Sculptra®. EU Instructions for Use. 2025. Available online. Accessed October 2026.

Haddad A, et al. International consensus: Sculptra®/Restylane® Skinboosters™ for non-facial rejuvenation. Poster presented at IMCAS 2026; January 29-31, 2026; Paris, France.

Galderma. Data on file. MA-48544 Subject satisfaction (GAIS) – NASHA and OBT Fillers. 2021.

Kablik J, et al. Comparative physical properties of HA dermal fillers. Dermatol Surg. 2009; 35, 302–312. doi: 10.1111/j.1524-4725.2008.01046.x.

Solish N, et al. Dynamics of HA fillers formulated to maintain natural facial expression. J Cosmet Dermatol. 2019;18(3):738-746. doi: 10.1111/jocd.12961.

Philipp‐Dormston WG, et al. Perceived naturalness of facial expression after HA filler injection in nasolabial folds and lower face. J Cosmet Dermatol. 2020;19(7):1600-1606. doi: 10.1111/jocd.1320.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20261005211995/en/

Permalink

https://www.aetoswire.com/en/news/0610202657830

Contacts

For further information:

Christian Marcoux, M.Sc.

Chief Communications Officer

christian.marcoux@galderma.com

+41 76 315 26 50

Richard Harbinson

Corporate Communications Director

richard.harbinson@galderma.com

+41 76 210 60 62

Céline Buguet

Franchises and R&D Communications Director

celine.buguet@galderma.com

+41 76 249 90 87

Emil Ivanov

Head of Strategy, Investor Relations, and ESG

emil.ivanov@galderma.com

+41 21 642 78 12

Jessica Cohen

Investor Relations and Strategy Director

jessica.cohen@galderma.com

+41 21 642 76 43

Invivoscribe® Advances Molecular Clonality Testing Portfolio with Comprehensive LymphoTrack® Flex Suite

  SAN DIEGO - Tuesday, 06. October 2026 AETOSWire Print 

New ultra-high sensitivity tests enable objective, automation-ready, high-throughput clonality and MRD workflow.

 

(BUSINESS WIRE)--Invivoscribe, a global leader in precision diagnostics and measurable residual disease (MRD) testing, today announced the launch of the complete LymphoTrack Flex suite, an integrated next-generation sequencing (NGS) solution to identify and track immunoglobulin and T-cell receptor gene rearrangements.

As NGS-based immune receptor MRD analysis moves from academic laboratories into routine use in oncology research centers, the demand for standardized, high-throughput workflows is accelerating. Laboratories are seeking both greater efficiency and ultra-high sensitivity. This requires increasing DNA inputs while ensuring higher testing throughput and analytical performance. Translational programs need testing that is both reproducible and scalable across sites. LymphoTrack Flex meets these demands, bringing seven molecular targets (IGHV leader, IGH FR1, IGH FR2, IGH FR3, IGK, TRB and TRG), together in one automation-ready workflow with massively parallel multiplexing and a powerful bioinformatics engine to provide objective analyses and tracking of clonal sequences.

“Clonality, somatic hypermutation, and measurable residual disease provide complementary molecular insights across the course of lymphoid malignancies, with growing relevance as treatment approaches evolve beyond fixed-duration therapy toward more dynamic, MRD-informed strategies,” said Brad Patay, Chief Medical Officer of Invivoscribe. “LymphoTrack Flex enables laboratories to characterize clonal populations at baseline and select sequence-specific clonotypes for longitudinal assessments, providing a consistent molecular picture of disease over time to support the evaluation of these evolving treatment approaches.”

The software portfolio provides flexibility across laboratory environments. LymphoTrack Software supports local, desktop-based analysis for labs that want to run testing independently on a single workstation. LymphoTrack Enterprise Software provides a centralized environment for high-throughput analysis, standardized reporting, and integration with laboratory and data infrastructures, enabling labs to scale testing volume without re-architecting laboratory workflow.

“Our vision is to give all laboratories access to optimized MRD assays, controls, and analysis software, with one standardized approach,” said Jeff Miller, CEO of Invivoscribe. “I am incredibly proud of the team behind LymphoTrack Flex. This release is the result of decades of multidisciplinary and international clinical laboratory experience.”

With the complete LymphoTrack Flex suite now available, laboratories can implement a flexible, scalable NGS workflow for clonality assessment, somatic hypermutation analysis, and sequence-based MRD research across a broad range of lymphoid malignancies. Laboratories ready to expand or standardize their NGS clonality and MRD capabilities can learn more at LymphoTrack Flex page or contact inquiry@invivoscribe.com to connect with an Invivoscribe specialist.

About Invivoscribe

Invivoscribe is a global, vertically integrated biotechnology company dedicated to Improving Lives with Precision Diagnostics®. For more than thirty years, Invivoscribe has advanced the quality of healthcare worldwide by delivering high-quality, standardized reagents, diagnostic assays, sample preparation systems, and bioinformatics solutions that support precision medicine. The company has a proven track record of partnering with pharmaceutical and biotechnology organizations to support clinical trial testing through its global laboratory network in the United States, Germany, Japan, and China, as well as to develop and commercialize companion diagnostics, leveraging deep expertise in regulatory strategy and laboratory services. By offering both distributable diagnostic kits to over 700 clinical laboratory customers and clinical testing services through its globally located clinical laboratory subsidiaries, LabPMM®, Invivoscribe is an ideal partner across the full diagnostic lifecycle - from development and clinical trials through regulatory submission and commercialization.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20261006900484/en/

Permalink

https://www.aetoswire.com/en/news/54616964

Contacts

For more information, visit www.invivoscribe.com, or contact inquiry@invivoscribe.com

 

Posiflex Unveils AI-Powered SCO Series Kiosk to Accelerate the Future of Self-Service Retail

 TAIPEI, Taiwan -

A modular, smarter self-checkout platform engineered for weighing, RFID, and loss-prevention automation across diverse retail environments

(BUSINESS WIRE) -- Posiflex Technology, Inc., a global leader in Point of Sale (POS) systems and Online-to-Offline (O2O) solutions, proudly introduces the SCO Series Self-Service Kiosks, an AI-powered platform designed to redefine self-service retail by offering flexible system configurations that support either precise weighing-scale transactions or RFID-enabled automated checkout.

Built to address the evolving needs of both traditional fresh-goods environments and modern RFID-driven retail concepts, the SCO Series enables retailers to elevate operational accuracy, accelerate checkout processes, and future-proof store deployments through modular architecture, intelligent automation, and adaptable form factors engineered for next-generation retail.

AI-Enabled Self-Checkout Solution for Weighing & RFID Applications

Designed for diverse retail environments, the SCO Series offers two dedicated configurations: a weighing-scale model for fresh and bulk goods and an RFID model for tag-enabled retail.

The weighing solution delivers fast and accurate pricing for fruits, vegetables, and bulk items, featuring a durable stainless-steel platform, seamless POS integration, and real-time weight display to ensure precise, efficient self-checkout.

The RFID configuration enables automatic item identification and multi-item contactless reading without barcode alignment, accelerating checkout while improving operational efficiency for apparel, specialty retail, and unattended store applications.

AI-Powered Loss Prevention for an Optimized Checkout Experience

At the core of the platform, AI-driven object recognition reduces manual input, minimizes mis-scanning, and supports behavior anomaly detection. Optional AI loss-prevention capabilities and a large LED status indicator provide real-time alerts, helping retailers easy monitoring, prevent scanning error, and maintain efficient checkout operations.

Modular and Scalable Design for Flexible Deployment

The SCO Series features a modular design that adapts to diverse retail environments and store layouts. Retailers can configure optional modules such as weighing scales, RFID detection, and payment peripherals, including MSR, NFC/RFID readers, and a dedicated EMV mounting bracket.

Powered by flexible Intel® platform options, the system delivers scalable performance for cost-effective deployment from pilot projects to large-scale rollouts.

Flexible Display Installation for User-Centric Design

The SCO Series features a 15.6-inch true-flat PCAP touch display with an optional 10-inch customer-facing display for enhanced engagement. To suit different store layouts, the main display can be installed on either the left or right side, supporting countertop, kiosk, and full-standing deployments.

Developer Tools & Seamless System Integration

Posiflex provides a comprehensive Software Development Kit (SDK) with developer documentation and integration tools, enabling partners to integrate with existing POS systems, build customized workflows, and support advanced features such as AI object recognition and AI loss prevention. This flexible development framework accelerates deployment while supporting evolving retail needs.

Expanding its self-service portfolio, the Posiflex SCO Series now supports floor-standing and countertop deployments, as well as the Datalogic MAGELLAN™ 9600i Module support. A dedicated weighing scale model is also scheduled for release soon, broadening the solution's suitability for supermarkets, grocery stores, and other retail environments.

The Posiflex SCO Series self-service kiosks empower retailers to modernize customer journeys, strengthen operational control, and deliver frictionless checkout experiences in today's rapidly evolving retail landscape.

Learn more about SCO Series, please visit the product landing page: https://www.posiflex.com/promotion/self-checkout-solutions-SCO-series/

About POSIFLEX Group

Posiflex Group is a global leader in Commercial AIoT platform powered by smart Online-to-Offline (O2O) and Scenario-defined Embedded Appliance Solutions. Pillared by three brands, Posiflex Group consists of Posiflex as a global top-5 brand in POS & Kiosk, Portwell as Embedded Foundry for AIoT Edge Compute, and KIOSK Information Systems (KIS) for managed self-service automation – together with a common mission to enable optimized productivity and superior customer journey across the connected world.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20261004628458/en/

Permalink

https://aetoswire.com/en/news/0610202657829

Contacts

Media Contact:

Jessie Hsu, Marketing Director, Global Marketing Division

jessiehsu@posiflex.com

 

New Global Survey Finds Majority of VMware Users Are Choosing Alternative Paths for Cost Control, Roadmap Flexibility and Better Support

LAS VEGAS - Tuesday, 06. October 2026

Rimini Street and DBTA/Unisphere Research survey finds 66% are already using or are considering third-party support

(BUSINESS WIRE) -- Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced findings from the 2026 IT Virtualization Survey – What’s Next for VMware Users, a new global survey of nearly 300 VMware user organizations conducted by Unisphere Research on behalf of Rimini Street.

Cost Cited as the Number One Factor in Seeking Alternative VMware Solutions

Key Findings: 90% of respondents said they are considering alternatives to VMware due to higher licensing costs, while 54% cited the end of perpetual license support as another reason to evaluate other options.

The research shows that cost remains the leading driver of virtualization roadmap decisions, with nearly three-quarters of respondents (73%) citing cost savings as a top priority. At the same time, organizations reported significant barriers to progress, including operational complexity (40%), multi-vendor management challenges (38%), securing the increased attack surface (37%) and team skills requirements (37%).

These findings suggest that while organizations are actively pursuing change, they are also looking for ways to reduce risk and avoid unnecessary disruption.

IT Leaders Choose Multiple and Hybrid Hypervisor Models for Greater Control and More Flexibility

Key Findings: 60% are considering a multiple-hypervisor strategy, reflecting growing interest in more flexible, mixed environments that support both operational and financial goals. In addition, 47% are favoring a hybrid IT virtualization environment consisting of hypervisors and containers for "best of both worlds" workload placement.

The findings also suggest that many organizations are considering a range of options beyond VMware Cloud Foundation (VCF). Nearly half of respondents (48%) said they do not currently plan to move any of their assets to VCF, indicating that many enterprises are taking a more measured approach and prioritizing strategies that align with their business needs, existing investments and operating models.

The trend shows increasing diversification in enterprise virtualization strategies with a longer-term transition toward bespoke, multi-platform IT virtualization environments. As organizations reevaluate their paths to modernization, they are increasingly adopting approaches that combine on-premises infrastructure, private cloud, public cloud and alternative hypervisors to support workload flexibility, operational efficiency and better cost control.

Majority of VMware Customers Consider Third-party Support to Protect and Extend the Life of VMware Investments

Key Findings: 66% of respondents are currently using or considering third-party support. Leading reasons cited include security (60%), installation and implementation support (57%), and service and support concerns (54%).

IT security leaders report being overwhelmed by the “vulnerability treadmill.” In virtualized IT environments, a single compromised virtual machine can expose hundreds of guest machines, increasing the risk of service outages and potential data breaches. This makes the hypervisor a high-value target for ransomware and advanced persistent threats.

As VMware customers reassess their virtualization strategies, many are exploring third-party VMware support to strengthen service coverage, maintain operational continuity and extend the value of existing investments. The findings suggest organizations want greater control over how they secure, support and evolve environments.

Further, 77% of IT virtualization security leaders said they would see value in a security solution that provides real-time threat visibility and proactive protection against vulnerabilities, rather than relying solely on Broadcom’s patching program. Together, these findings point to growing demand for more resilient, security-by-design virtualization strategies.

“The shift for current VMware users is not simply about replacing one vendor with another. It reflects a broader effort by enterprises to reduce dependency on a single provider, maintain continuity for mission-critical systems and modernize at a pace that fits their own business requirements,” cited Joe McKendrick, lead analyst, Unisphere Research. “For many organizations, that means balancing support for existing environments with new investments designed to improve resilience, security and scalability over time.”

“Organizations want more choice, flexibility and control over their virtualization strategies,” said Keith Costello, EVP and chief operating officer, Rimini Street. “Our suite of services for VMware helps clients reduce costs, strengthen security, improve support outcomes and extend the value of their existing VMware investments — without being forced into disruptive timelines or one-size-fits-all vendor roadmaps. These survey findings reinforce the need for practical, vendor-independent strategies that put business priorities back on the client’s terms.”

Access the full report, 2026 IT Virtualization Survey – What’s Next for VMware Users, available for download.

Survey methodology

The survey was conducted by Unisphere Research in partnership with Rimini Street. Unisphere Research is the market research unit of Unisphere Media, a division of Information Today, Inc., publishers of Database Trends and Applications magazine and the 5 Minute Briefing newsletters. It surveyed 269 executives, managers and professionals across VMware user organizations between December 2025 and February 2026 to assess current usage, future plans and perceptions of VMware under Broadcom, as well as interest in alternative solutions. All respondents were current users of VMware solutions at the time the survey was conducted.

About Rimini Street, Inc.

Rimini Street, Inc. (Nasdaq: RMNI), a Russell 2000® Company, is a proven, trusted global provider of end-to-end, mission-critical enterprise software support, managed services and innovative Agentic AI ERP solutions, and is the leading third-party support provider for Oracle, SAP and VMware software. The Company has signed thousands of IT service contracts with Fortune Global 100, Fortune 500, midmarket, public sector and government organizations who have leveraged the Rimini Smart Path™ methodology to achieve better operational outcomes, billions of US dollars in savings and fund AI and other innovation.

To learn more, please visit www.riministreet.com, and connect with Rimini Street on X, Facebook, Instagram, and LinkedIn.

Forward-Looking Statements

Certain statements included in this communication are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “anticipate,” “assume,” “believe,” “budget,” “continue,” “could,” “currently,” “estimate,” “expect,” “forecast,” “future,” “intend,” “may,” “might,” “outlook,” “plan,” “possible,” “goal,” “potential,” “predict,” “project,” “reflect,” “results,” “seem,” “seek,” “should,” “will,” “would” and other similar words, phrases or expressions. These forward-looking statements include, but are not limited to, statements regarding our expectations of future events, future opportunities, global expansion and other growth initiatives and our investments in such initiatives. These statements are based on various assumptions and on the current expectations of management and are not predictions of actual performance, nor are these statements of historical facts. These statements are subject to a number of risks and uncertainties regarding Rimini Street’s business, and actual results may differ materially. These risks and uncertainties include, but are not limited to our ability to attract new clients or retain and/or sell additional products or services to existing clients; our ability to achieve and maintain an adequate rate of revenue growth; cost of revenue, including changes in costs associated with our efforts to grow and the results of any efforts to manage costs to align with current revenue expectations and the expansion of our offerings; the effects of increased intense competition in our industry and our ability to compete effectively; our ability to successfully educate the market regarding the advantages of our support and managed services for ERP software and to sell the products and services comprising our “Rimini Smart Path™” solutions portfolio, including but not limited to our Agentic AI ERP solutions; our intentions with respect to our pricing model and expectations of client savings relative to use of other providers; the evolution of the ERP software management and support landscape facing our clients and prospects; estimates of our total addressable market; the effects of seasonal trends on our results of operations, including the contract renewal cycles for vendor-supplied software support and managed services; the effects of the efforts of enterprise software vendors to sell upgrades or migrations to cloud-based versions of their enterprise software on our results of operations; our ability to scale our operations quickly enough to meet our clients’ changing needs or decrease our costs adequately in response to changing client demand; risks arising from incorporating artificial intelligence (“AI”) technologies into our products or services or any deficiencies associated with AI technologies used by us or by our third-party vendors and service providers; our ability to maintain, protect, and enhance our brand; the loss of one or more members of our management team and our ability to attract and retain additional qualified technical, sales and marketing personnel; our ability to expand our marketing and sales capabilities; our ability to avoid interruptions to, or degraded performance of, our services and the impact of any such interruptions or performance problems on our operations; our ability to defend against cybersecurity threats and to comply with data protection and privacy regulations; our expectations regarding new product offerings, innovation solutions, partnerships and alliance programs and our ability to develop and maintain strategic partnerships; our ability to expand internationally and the risks associated with global operations; our wind down of support services for Oracle’s PeopleSoft software products and the impact on future period revenue and costs incurred related to these efforts; the continuing impact of and our ability to comply with the terms of our July 2025 settlement agreement with Oracle; the impact of macro-economic trends, including inflation and changes in foreign exchange rates, as well as general financial, economic, regulatory and political conditions affecting the industry in which we operate and the industries in which our clients operate; our ability to generate significant capital through our operations or to raise additional capital necessary to fund and expand our operations and invest in new services and products; our business plan and our ability to effectively secure and manage our growth and associated investments; risks relating to retention rates, including our ability to accurately predict retention rates; our ability to protect our intellectual property; our ability to maintain an effective system of internal control over financial reporting; changes in laws or regulations, including tax laws or unfavorable outcomes of tax positions we take; tariff costs; our ability to realize benefits from our net operating losses; any negative impact of environmental, social and governance (“ESG”) matters on our reputation or business and the exposure of our business to additional costs or risks from our reporting on such matters; our credit facility’s ongoing debt service obligations and financial and operational covenants on our business and related interest rate risk; the sufficiency of our cash and cash equivalents to meet our liquidity requirements; the volatility of our stock price; the amount and timing of repurchases, if any, under our stock repurchase program and our ability to enhance stockholder value through such program; our ability to maintain our good standing with the United States and international governments and capture new contracts with public sector entities; the occurrence of catastrophic events that may disrupt our business or that of our current and prospective clients; future acquisitions of, or investments in, complementary companies, products, subscriptions or technologies; and those discussed under the heading “Risk Factors” in Rimini Street’s Quarterly Report on Form 10-Q filed on July 30, 2026, and as updated from time to time by Rimini Street’s future Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and other filings by Rimini Street with the U.S. Securities and Exchange Commission. In addition, forward-looking statements provide Rimini Street’s expectations, plans or forecasts of future events and views as of the date of this communication. Rimini Street anticipates that subsequent events and developments will cause Rimini Street’s assessments to change. However, while Rimini Street may elect to update these forward-looking statements at some point in the future, Rimini Street specifically disclaims any obligation to do so, except as required by law. These forward-looking statements should not be relied upon as representing Rimini Street’s assessments as of any date subsequent to the date of this communication.

© 2026 Rimini Street, Inc. All rights reserved. “Rimini Street” is a registered trademark of Rimini Street, Inc. in the United States and other countries, and Rimini Street, the Rimini Street logo, and combinations thereof, and other marks marked by TM are trademarks of Rimini Street, Inc. All other trademarks remain the property of their respective owners, and unless otherwise specified, Rimini Street claims no affiliation, endorsement, or association with any such trademark holder or other companies referenced herein.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20261006014490/en/

Permalink

https://www.aetoswire.com/en/news/0610202657859

Contacts

Janet Ravin

VP, Corporate Marketing

Rimini Street, Inc.

+1 702 285-3532

pr@riministreet.com